IRF8 and B-cell non-Hodgkin lymphoma: To that end, we examined cohorts of syngeneic B cell lymphoma developed with A20 cells expressing IRF8 WT, N87Y, Q392X, or I424T (thus covering the two functional domains/clusters of IRF8 mutation in DLBCL, as well as missense and truncating mutations) grown in syngeneic BalbC mice (attempts to engraft 2PK-3 cells in BalbC mice were unsuccessful).